{
    "eid": "2-s2.0-84954048664",
    "title": "Tipranavir/ritonavir (500/200 mg and 500/100 mg) was virologically non-inferior to lopinavir/ritonavir (400/100 mg) at week 48 in treatment-Na\u00efve HIV-1-infected patients: A randomized, multinational, multicenter trial",
    "cover-date": "2016-01-05",
    "subject-areas": [
        {
            "$": "Multidisciplinary",
            "@code": "1000"
        }
    ],
    "keywords": [],
    "authors": [
        "David A. Cooper"
    ],
    "citedby-count": 5,
    "ref-count": 39,
    "ref-list": [
        "Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-Week results of the RESIST-2 trial",
        "Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials",
        "Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults",
        "Antiretroviral treatment of adult HIV infection: 2014 Recommendations of the International Antiviral Society-USA panel",
        "Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study",
        "Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial",
        "Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study",
        "Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: Randomised, double-blind, phase 3, non-inferiority study",
        "Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study",
        "Week 48 results from a randomized clinical trial of rilpivirine/ emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/ tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults",
        "Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis",
        "Resistance profile of etravirine: Combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies",
        "Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study",
        "Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (Argenta)",
        "Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients",
        "Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes",
        "Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: A decade of experience",
        "Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir",
        "Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study.",
        "Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level Viremia",
        "HIV drug resistance detected during low-level Viraemia is associated with subsequent virologic failure",
        "Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multicohort study",
        "Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples",
        "HIV-1 drug resistance in newly infected individuals",
        "Genetic correlates of in vivo viral resistance to Indinavir, a human immunodeficiency virus type 1 protease inhibitor",
        "Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy",
        "Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients",
        "Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir",
        "Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers",
        "A 14-Day Dose-Response Study of the Efficacy, Safety, and Pharmacokinetics of the Nonpeptidic Protease Inhibitor Tipranavir in Treatment-Naive HIV-1-Infected Patients",
        "Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-Week analysis from the RESIST-1 trial",
        "Tipranavir: A new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients",
        "Update of the drug resistance mutations in HIV-1: Spring 2008.",
        "Paper Presented At: 8th International Congress on Drug Therapy in HIV Infection",
        "Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients",
        "Stanford University HIV Resistance Database",
        "Incidence of Resistance in a Double-Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and Lamivudine",
        "Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents"
    ],
    "affiliation": [
        {
            "affiliation-city": "Rio de Janeiro",
            "affilname": "GlaxoSmithKline Brasil Ltda.",
            "affiliation-country": "Brazil"
        },
        {
            "affiliation-city": "Ridgefield",
            "affilname": "Boehringer Ingelheim Pharmaceuticals, Inc.",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Berlin",
            "affilname": "Vivantes Auguste-Viktoria-Klinikum",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Kensington",
            "affilname": "The Kirby Institute",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Ingelheim am Rhein",
            "affilname": "Boehringer Ingelheim International GmbH",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Basel",
            "affilname": "Novartis International AG",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Berlin",
            "affilname": "Humboldt-Universit\u00e4t zu Berlin",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": null,
            "affilname": "Pesquisa E Ensino",
            "affiliation-country": "Brazil"
        }
    ],
    "funding": [
        "National Institute of Allergy and Infectious Diseases",
        "National Institute of Allergy and Infectious Diseases",
        "Boehringer Ingelheim"
    ]
}